SHSE:600062's Gross Margin % is ranked better than 64.71% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs SHSE:600062: 57.56
China Resources Double-Crane Pharmaceutical Co had a gross margin of 59.03% for the quarter that ended in Mar. 2026 => Durable competitive advantage
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
China Resources Double-Crane Pharmaceutical Co had a gross margin of 59.03% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
China Resources Double-Crane Pharmaceutical Co Gross Margin % Related Terms
China Resources Double-Crane Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Gross Margin % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
SHSE:600062 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Gross Margin % of 59.03% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is near median its historical median of 57.35. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Gross Margin % has ranged from 53.11 to 63.43. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #331 out of 938 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is China Resources Double-Crane Pharmaceutical Co's Gross Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current Gross Margin % of 59.03% is near median its 10-year median of 57.35. Over the past 10 years, this metric has ranged from a low of 53.11 to a high of 63.43. The Drug Manufacturers industry median Gross Margin % is 48.54. China Resources Double-Crane Pharmaceutical Co's value of 59.03% is 21.6% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #331 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #331 out of 938 companies for Gross Margin %. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median Gross Margin % is 48.54. China Resources Double-Crane Pharmaceutical Co's value of 59.03% is 21.6% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Gross Margin % has ranged from 53.11 to 63.43 over the past decade. While the company's 10-year median is 57.35 vs. the industry median of 48.54, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Gross Margin % of 59.03% is 21.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Gross Margin % is 59.03%, which is near median its own 10-year median of 57.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current Gross Margin % is 59.03%, which is near median its 10-year median of 57.35 and 21.6% above the Drug Manufacturers industry median of 48.54. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Gross Margin % is 59.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Gross Margin %: 59.03% (near median its 10-year median of 57.35)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 21.6% above the Drug Manufacturers median (#331 of 938)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
